Extracellular Vesicles for Cancer Therapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: 28 February 2025 | Viewed by 1005

Special Issue Editors


E-Mail Website
Guest Editor
Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP) & RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal
Interests: biology; genetics and epigenetics; molecular biology; extracellular vesicles and biological sciences; health; nanomedicine; oncology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP) & RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-072 Porto, Portugal
Interests: biochemistry; genetics and epigenetics; molecular biology; extracellular vesicles; nanomedicine; biological sciences
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In the last few years, extensive research has been conducted on the role of extracellular vesicles (EVs) in cellular communication and tumor microenvironment modulation. In fact, major intercellular players are involved in physiological and pathological processes, representing the first form of cell-to-cell communication. EVs are nano-sized lipid-bilayer-encapsulated particles that are released by practically all types of cells in the three domains of life, carrying several biologically active molecules from parental cells, including proteins, lipids, sugars, DNA and RNA, namely non-coding RNAs, such as microRNAs and long-non-coding RNAs. Accumulating evidence demonstrates that they can act both locally and at distant sites modulating tumor growth, invasion, angiogenesis, immune inhibition and establishment of pre-metastatic niches. In fact, EVs can circulate to distant organs and induce changes in the microenvironment that potentiate future metastatic spread through horizontally transferring molecular information. Moreover, their stability when circulating in different body fluids and ability to transfer bioactive molecules between cells indicates their potential for the design of new therapeutic approaches. In the last years, their usage as different drug carriers, in alternative to the classic liposomes, has been widely studied showing great potential, in different therapeutic modalities such as, gene therapy or immune modulation, with the known cancer vaccines.

Therefore, this Special Issue aims to highlight the potential of utilizing EVs in new cancer therapies, covering their characterization, in a functional sense, in the different oncological sets and their potential as therapeutic agents, due to their innate therapeutic properties, or even as engineered therapeutic vehicles for known drugs or vaccines.

Dr. Ana Luísa Teixeira
Dr. Mariana Morais
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liposomes

  • exosomes
  • electroporation
  • transfection
  • RNA technologies
  • vaccines
  • targeted therapy
  • immunology
  • gene therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

23 pages, 1385 KiB  
Review
MicroRNAs as Promising Therapeutic Agents Against Prostate Cancer Resistant to Castration—Where Are We Now?
by Mariana Ferreira, Mariana Morais, Rui Medeiros and Ana Luísa Teixeira
Pharmaceutics 2024, 16(11), 1347; https://doi.org/10.3390/pharmaceutics16111347 - 22 Oct 2024
Viewed by 659
Abstract
MicroRNAs are a conserved class of small, tissue-specific, non-coding RNAs that regulate gene expression to preserve cellular homeostasis. Proper miRNA expression is crucial for physiological balance because it affects numerous genetic pathways, including cell cycle control, proliferation, and apoptosis, through gene expression targeting. [...] Read more.
MicroRNAs are a conserved class of small, tissue-specific, non-coding RNAs that regulate gene expression to preserve cellular homeostasis. Proper miRNA expression is crucial for physiological balance because it affects numerous genetic pathways, including cell cycle control, proliferation, and apoptosis, through gene expression targeting. Deregulated miRNA expression has been implicated in several cancer types, including prostate cancer (PC), acting as tumor suppressors or oncogenes. Despite the availability of promising therapies to control tumor growth and progression, effective diagnostic and therapeutic strategies for different types of cancer are still lacking. PC continues to be a significant health challenge, particularly its castration-resistant (CRPC) form, which presents major therapeutic obstacles because of its resistance to conventional androgen deprivation treatments. This review explores miRNAs’ critical roles in gene regulation and cancer biology, as well as various miRNA delivery systems, highlighting their potential and the challenges in effectively targeting cancer cells. It aims to provide a comprehensive overview of the status of miRNA research in the fight against CRPC, summarizing miRNA-based therapies’ successes and limitations. It also highlights the promise of miRNAs as therapeutic agents for CRPC, underlining the need for further research to overcome existing challenges and move these therapies toward clinical applications. Full article
(This article belongs to the Special Issue Extracellular Vesicles for Cancer Therapy)
Show Figures

Graphical abstract

Back to TopTop